Role of Drug Discovery in Central Nervous System Disorders: An Overview

Mohit Gupta; Ravi Shekhar; Jagdish K Sahu

doi:10.24092/CRPS.2021.110302

Mohit Gupta IIMT College of Medical Sciences, IIMT University, Meerut (U.P.)
Ravi Shekhar Department of Pharmacy, Dr. Bhimrao Ambedkar University, Agra (U.P.)
Jagdish K Sahu School of Pharmacy and Technology Management, SVKM’S NMIMS (Deemed to be University), Shirpur, Distt. – Dhule, Maharashtra

DOI https://doi.org/10.24092/CRPS.2021.110302

Abstract

Central nervous system (CNS) stimulants are drugs, which produce a response that could be used to alleviate a particular medical condition. These are the agents, which speed up to treat conditions characterized by lack of adrenergic stimulation, including narcolepsy and neonatal apnea. The majority of CNS stimulants is chemically similar to the neurohormone norepinephrine and simulates the traditional "fight or flight" syndrome associated with sympathetic nervous system arousal. A small figure of added members of the CNS stimulant class do not fall into definite chemical groups. The review on central nervous system stimulants gives detail study of CNS stimulant drugs, their mechanism of action and in vivo models of CNS stimulants.

The brain is a delicate tissue, and advancement built very effective methods to guard it. Unfortunately, the same mechanisms that protect it against intrusive chemicals can also upset therapeutic interventions. Many current medications are rendered unsuccessful in the treatment of cerebral maladies due to our incapability to efficiently deliver and sustain them within the brain.

Keywords: CNS Stimulants, Blood brain barrier (BBB), Drug toxicity, Drug Safety

References

1. Mouritsen OG, Jorgensen K. A new look at lipid membrane structure in relation to drug research. Pharm. Res. 1998; 15: 1507–1519.
2. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 1997; 49: 403– 449.
3. Williams M, Coyle JT, Shaikh S, Decker MW. Same brain, new decade: challenges in CNS drug discovery in the postgenomic, proteomic era. Annu. Rep. Med. Chem. 2001; 36: 1–10.
4. Bannon WW, Deceker MW, Holladay MW, Curzon P, Donelly-Roberts D, Puttfarcken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD, Williams M, Arneric SP. Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science. 1998; 279: 77– 81.
5. Daly JW, Myers CW, Whittaker N. Further classification of skin alkaloids from neotropical poison frogs (Dendrobatidae), with a general survey of toxic/ noxious substances in the amphia. Toxicon. 1987; 25:1023–1095.
6. Lenz GR (1999) Technical problems in getting results. In: From data to drugs: strategies for benefiting from the new drug discovery technologies (Haberman, AB, Lenz GR, Vaccaro DE eds.), pp 95–114. London: Scrip Reports.
7. Pardridge WM. The blood-brain barrier and neurotherapeutics. NeuroRx. 2005; 2:1–2. Banks W. Characteristics of compounds that cross the blood-brain barrier. BMC Neurology. 2009; 9:S3.
8. Banks WA. Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease. BMC Neurosci. 2008; 9, Suppl 3:S2.
9. Barchet TM, Amiji MM. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert. Opin. Drug. Deliv. 2009; 6: 211-25.
10. Schneeberger EE, Lynch RD. Structure, function, and regulation of cellular tight junctions. Am J Physiol (Lond). 1992; 262: L647–L661.
11. Faasen F, Vogel G, Spanings H, Vromans H. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int. J. Pharm. 2003; 263:113–122.
12. Graff CL, Pollack GM. Drug transport at the blood-brain barrier and the choroid plexus. Curr. Drug. Metab. 2004; 5: 95–108.
13. Pardridge WM. CNS drug design based on principles of blood brain barrier transport. J. Neurochem. 1998; 70: 1781–1792.
14. Schlosshauer B, Steuer H. Comparative anatomy, physiology and in vitro models of the blood-brain and blood-retina barrier. Curr. Med. Chem. - Central Nervous System Agents. 2002; 2:175–186.
15. Sippl W. Computational approaches for the prediction of blood brain barrier permeation. Curr. Med. Chem. – Central Nervous System Agents. 2002; 2: 211–227.
16. Rautio J, Kumpulainen H, Heimbach T. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 2008; 7(3): 255–270.
17. Rautio J, Laine K, Gynther M, Savolainen J. Prodrug approaches for CNS delivery. AAPS. 2008; 10(1): 92–102.
18. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science. 1972; 178(64): 984–986.
19. Bodor N, Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev. 1999; 36(2–3), 229–254.
20. Bodor N, Buchwald P. Barriers to remember: brain-targeting chemical delivery systems and Alzheimer’s disease. Drug Discov. Today. 2002; 7(14), 766–774.
21. Bleicher KH, Bohm HJ. Hit and lead generation: beyond highthroughput screening. Nat. Rev. Drug Discov. 2003; 2: 369-378.
22. Pardridge WM. Molecular Trojan horses for blood-brain barrier drug delivery. Curr. Opin. Pharmacol. 2006; 6: 494-500.
23. Sahu JK, Mishra AK. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review. Current Molecular Pharmacology 2018; 11(4): 270-278.
24. Chico LK, Van Eldik LJ. Targeting protein kinases in central nervous system disorders. Nat. Rev. Drug Discov. 2009; 8, 892-909.